SCHEMBL3666480

SCHEMBL3666480

CCOc1ccc(C(C)C(=O)O)cc1OCC

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 6/20 0.63
AKR1C2 P52895 6/20 0.63
PTGS2 P35354 7/20 0.59
PTGS1 P23219 3/20 0.59
HIF1A Q16665 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TSHR P16473 2/20 0.47
CDC42 P60953 1/20 0.47
RAC1 P63000 1/20 0.47
CYP1A2 P05177 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TNF P01375 1/20 0.46
NPC1 O15118 1/20 0.45
USP2 O75604 1/20 0.45
RAB9A P51151 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3673327 0.92 HIF1A (0.59) AKR1C3AKR1C2PTGS2PTGS1HIF1A
SCHEMBL7995945 0.91 HIF1A (0.57) AKR1C3AKR1C2PTGS2PTGS1HIF1A
SCHEMBL7995934 0.91 HIF1A (0.57) AKR1C3AKR1C2PTGS2PTGS1HIF1A
SCHEMBL10921479 0.89 F2 (0.58) AKR1C3AKR1C2PTGS2PTGS1SMN1; SMN2
SCHEMBL3667215 0.87 AKR1C3 (0.52) AKR1C3AKR1C2PTGS2PTGS1TSHR
SCHEMBL3667757 0.86 AKR1C3 (0.55) AKR1C3AKR1C2PTGS2PTGS1SMN1; SMN2
SCHEMBL6612965 0.83 AKR1C3 (0.55) AKR1C3AKR1C2PTGS1SMN1; SMN2NPSR1
SCHEMBL6627302 0.80 NPSR1 (0.48) AKR1C3AKR1C2PTGS1SMN1; SMN2NPSR1
SCHEMBL4684868 0.80 HIF1A (0.59) AKR1C3AKR1C2HIF1ASMN1; SMN2NPSR1
SCHEMBL6055134 0.79 ALDH1A1 (0.48) HIF1ASMN1; SMN2NPSR1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110386893-A Isoindole derivatives 天津合美医药科技有限公司 2019-10-29 CN disclosed
CN-101475526-B Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof TEXAS BIOTECHNOLOGY CORP 2011-05-25 CN disclosed
US-7812038-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
CN-101475526-A Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof TEXAS BIOTECHNOLOGY CORP (US) 2009-07-08 CN disclosed
CN-100491353-C Carboxylic acid derivatives inhibiting the binding of integrins to their receptors TEXAS BIOTECHNOLOGIES CORP (US) 2009-05-27 CN disclosed
US-7439258-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2008-10-21 US disclosed
US-7439258-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2008-10-21 US disclosed
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors BIEDIGER RONALD J 2006-12-07 US disclosed
US-6972296-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. (US) 2005-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, ITGA1 AKR1C3 809/4885AKR1C2 844/4885PTGS2 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.